Fluocinolone Acetonide implant injected 1 month after Dexamethasone implant for diabetic macular oedema: the ILUVI1MOIS study - Archive ouverte HAL Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2023

Fluocinolone Acetonide implant injected 1 month after Dexamethasone implant for diabetic macular oedema: the ILUVI1MOIS study

Résumé

OBJECTIVE The aim of this study was to assess the efficacy and safety of fluocinolone acetonide implant (FAci) injected 1 month after the last dexamethasone intravitreal implant (DEXi) in chronic diabetic macular oedema (DME) patients. METHODS Retrospective multicentric study conducted in pseudophakic patients with chronic DME frequently treated with DEXi (time to DME recurrence ≤6 months), receiving FAci 1 month after the last DEXi, with at least a 6-month follow-up. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure (IOP) and additional treatments were assessed on the day of FAci injection (M0), one (M1) and 3 months (M3) later and then every 3 months. RESULTS Forty-one eyes of 34 patients were included. At M0, patients’ mean age was 68.7 ± 9.8 years, the mean DME duration was 63.9 ± 22.9 months, the mean interval between two DEXi was 14.2 ± 3.3 weeks. M12 data were available for 71% of patients. At baseline, the mean BCVA, CMT and IOP were 63.2 ± 16.6 letters, 299.4 ± 103.3 µm, and 16.2 ± 4.5 mmHg, respectively, and remained stable during the follow-up. At M12, 14% of patients required additional intravitreal treatments. CONCLUSION In pseudophakic patients with chronic DME showing good response to DEXi but requiring repeated injections every <6 months, switching to FAci 1 month after the last DEXi was effective and safe. Further prospective randomized controlled studies are needed to confirm these findings, and to determine the best interval between the last DEXi and the first FAci.
Fichier principal
Vignette du fichier
ILUVI1MOIS_preprint.pdf (375.44 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-04073664 , version 1 (19-04-2023)

Licence

Identifiants

  • HAL Id : hal-04073664 , version 1

Citer

Nicolas Rousseau, Olivier Lebreton, Hélène Masse, Yann Maucourant, Valentin Pipelart, et al.. Fluocinolone Acetonide implant injected 1 month after Dexamethasone implant for diabetic macular oedema: the ILUVI1MOIS study. 2023. ⟨hal-04073664⟩
35 Consultations
31 Téléchargements

Partager

Gmail Mastodon Facebook X LinkedIn More